Display Technologies

Contact Us

Phage and mRNA Display: Complementary Platforms for Demanding Targets

Two complementary display platforms power our search for rare, high-affinity binders: phage display, built on decades of in-house expertise across peptide and antibody libraries, and a fully cell-free mRNA display platform screening up to 10¹³ variants for targets that have resisted conventional screening.

Together they broaden the range of targets we can address for partners.

  • Phage Display: A Cutting-Edge Technique for Drug Discovery

    Phage display is a powerful technique for interrogating vast arrays of molecules quickly and efficiently. Through iterative rounds of panning, rare binders can be selected to support drug discovery efforts. At IRBM, our extensive expertise, state-of-the-art phage display technology, and complex phage libraries (peptide and antibody) ensure the identification of strong leads for any drug discovery program.

  • Integrated Process for Lead Identification

    We specialize in screening receptors both in vitro and in vivo, enabling the discovery of the best candidates for your project. Whether targeting protein-protein interactions, searching for co-agonists, or developing anti-tumor antibodies, our tailored approaches deliver actionable results.

    IRBM’s integrated workflow ensures seamless transitions from library construction and selection to in vivo assessments:

    • Affinity selection: Vast libraries are interrogated to identify rare and high-affinity binders.
    • Automated workflows: Our advanced screening, sequencing, and confirmation processes allow thousands of phage clones to be analyzed quickly and efficiently.

  • Targeting Physiological Conditions

    To identify binders that recognize targets under physiological conditions, we perform affinity selection on cells both in vitro and in vivo. This enables the discovery of candidates that function in complex biological contexts, such as blood-brain barrier penetration.

    For antibodies, we use our affinity maturation library to enhance binding properties. When optimizing peptides, our specialist peptide chemistry team employs an extensive range of modification and analytical techniques to refine putative leads.

mRNA Display for Ultra-Large Peptide Libraries

For therapeutic peptide programs, we complement phage display with mRNA display, a fully cell-free platform that screens up to 10¹³ unique variants and expands accessible molecular diversity by three orders of magnitude. Macrocyclic architectures are generated directly from the primary screen through Cys-Cys cyclization, and NGS-based enrichment monitoring guides selection at every round. Standard campaigns deliver high-specificity binders in the nanomolar to picomolar range.

Where a target has resisted conventional screening, mRNA display broadens the search space and brings previously inaccessible binders within reach.

Phage Display Bio-Panning Cycle

Diagram illustrating the IRBM bio-panning process for isolating rare binders to a target through iterative rounds of affinity selection, including steps for incubation, washing, elution, and amplification using solid supports like biotin-target on beads and Fc-chimera on PA-beads.
Let’s Talk About Your Display Project

Relevant Publications

Preview of the IRBM poster on Surface Plasmon Resonance technology for the identification of new therapeutic agents from phage display libraries.

In this work, we highlight how IRBM leverages Surface Plasmon Resonance (SPR) technology as a crucial part of the screening process for therapeutic peptides and monoclonal antibodies.

View and Download

Start a conversation.

Great science begins here.

Back To Top
No results found...